Press Releases

Investors

Press Releases

Date Title and Summary Additional Formats
Toggle Summary Arrowhead Pharmaceuticals to Webcast Fiscal 2020 First Quarter Results
PASADENA, Calif. --(BUSINESS WIRE)--Jan. 22, 2020-- Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it will host a webcast and conference call on February 5, 2020 , at 4:30 p.m. EST to discuss its financial results for the fiscal first quarter ended December 31, 2019 .
View HTML
Toggle Summary Arrowhead Pharmaceuticals Appoints James Hassard as Chief Commercial Officer
PASADENA, Calif. --(BUSINESS WIRE)--Jan. 6, 2020-- Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced the appointment of James Hassard to the newly-created position of chief commercial officer. Mr. Hassard will be responsible for driving commercial strategy and building the team and
View HTML
Toggle Summary Arrowhead Pharmaceuticals Doses First Patient in AROAAT2002 Open Label Phase 2 Study of ARO-AAT for Treatment of Alpha-1 Liver Disease
PASADENA, Calif. --(BUSINESS WIRE)--Dec. 20, 2019-- Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it has dosed the first patient in AROAAT2002, an open-label Phase 2 clinical study of ARO-AAT, the company’s second generation investigational RNA interference (RNAi) therapeutic
View HTML
Toggle Summary Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Marketplace Rule 5635(c)(4)
PASADENA, Calif. --(BUSINESS WIRE)--Dec. 16, 2019-- Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that as an inducement to entering into employment with the Company, on December 6, 2019 , the Compensation Committee of the Board of Directors approved "inducement" grants to 21 new
View HTML
Toggle Summary Arrowhead Pharmaceuticals Files for Regulatory Clearance to Begin Phase 1 Study of ARO-HSD for Treatment of Alcohol and Nonalcohol Related Liver Disease
PASADENA, Calif. --(BUSINESS WIRE)--Dec. 16, 2019-- Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it has filed an application for approval to begin a Phase 1 clinical trial of ARO-HSD, the company’s investigational RNA interference (RNAi) therapeutic being developed as a
View HTML
Toggle Summary Arrowhead Pharmaceuticals Appoints Marianne De Backer to Board of Directors
PASADENA, Calif. --(BUSINESS WIRE)--Dec. 13, 2019-- Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that the board of directors appointed veteran pharmaceutical industry executive Marianne De Backer , Ph.D., as an independent director of the company, with a term beginning effective
View HTML
Toggle Summary Arrowhead Pharmaceuticals Files IND for Phase 1b Study of ARO-HIF2 for Treatment of Clear Cell Renal Cell Carcinoma
PASADENA, Calif. --(BUSINESS WIRE)--Dec. 11, 2019-- Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it has submitted an Investigational New Drug (IND) application to the U.S. Food and Drug Administration ( FDA ) for a Phase 1b adaptive dose-finding clinical study of ARO-HIF2, the
View HTML
Toggle Summary Arrowhead Pharmaceuticals Closes Underwritten Public Offering with Gross Proceeds of $266.8 Million
PASADENA, Calif. --(BUSINESS WIRE)--Dec. 6, 2019-- Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that on December 6, 2019 it closed the previously announced underwritten public offering of 4,600,000 shares of its common stock, which included shares issued upon the exercise in full
View HTML
Toggle Summary Arrowhead Pharmaceuticals Announces Pricing of Underwritten Public Offering of Common Stock
PASADENA, Calif. --(BUSINESS WIRE)--Dec. 4, 2019-- Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced the pricing of an underwritten public offering of 4,000,000 shares of its common stock, offered at a price of $58.00 per share, before underwriting discounts.
View HTML
Toggle Summary Arrowhead Pharmaceuticals Announces Proposed Underwritten Offering of Common Stock
PASADENA, Calif. --(BUSINESS WIRE)--Dec. 2, 2019-- Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced its intention to offer and sell 4,000,000 shares of its common stock in an underwritten offering pursuant to its existing automatic shelf registration statement.
View HTML